Table 1.

Overview of ocular surface immune-related adverse events for ipilimumab and nivolumab in the literature

First author	Age/sex	Current immunotherapy	Previous immunotherapies	Ocular surface immune-related adverse events	Treatment for immune-related adverse events	Outcome of ocular complaints
Papavasileiou [6]	55/F	Ipilimumab, bevacizumab	Not reported	Peripheral ulcerative keratitis	Topical corticosteroids, topical antibiotics, acyclovir	Resolved
Voskens [17], 2013	57/M	Ipilimumab	DTIC, sorafenib	Conjunctivitis	Lubrication	Resolved
Voskens [15], 2012	53/F	Ipilimumab	Dacarbazine, sorafenib	Iridocyclitis, marginal keratitis	Systemic corticosteroids	Resolved
Henderson [18]	55/M	Ipilimumab	Not reported	Episcleritis, orbital inflammation	Topical steroids	Improved
Zimmer [4]	78/M	Nivolumab	Interferon-α	Conjunctivitis	Topical corticosteroids	Not resolved
	49/F	Nivolumab	Vemurafenib, dabrafenib, ipilimumab	Dry eyes	Topical therapy	Not resolved
Nguyen [7]	58/M	Nivolumab	Not reported	Dry eyes; corneal perforation	Lubrication, topical cyclosporine, punctal occlusion	Improved
	46/F	Nivolumab	Not reported	Dry eyes	Lubrication, topical cyclosporine	Improved
Montaudie [16]	56/M	Nivolumab	Not reported	Dry eyes, sarcoidosis	Systemic corticosteroids	Resolved